Trial Profile
Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2021
Price :
$35
*
At a glance
- Drugs LP 0145 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors LEO Pharma
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2021 Planned End Date changed from 1 Jan 2021 to 12 May 2021.
- 17 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 12 May 2021.